## II. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in this application.

1-18. Canceled.

19. (Original) A compound of formula III:



III

wherein

$R^4$ is a divalent group of the formula:

$$-(R^{4a})_d-(A^1)_e-(R^{4b})_f-Q-(R^{4c})_g-(A^2)_h-(R^{4d})_i-$$

wherein

d, e, f, g, h and i are each independently selected from 0 and 1;

$R^{4a}$, $R^{4b}$, $R^{4c}$ and $R^{4d}$ are each independently selected from (1-10C)alkylene, (2-10C)alkenylene and (2-10C)alkynylene, wherein each alkylene, alkenylene or alkynylene group is unsubstituted or substituted with from 1 to 5 substituents independently selected from (1-4C)alkyl, fluoro, hydroxy, phenyl and phenyl-(1-4C)alkyl;

$A^1$ and $A^2$ are each independently selected from (3-7C)cycloalkylene, (6-10C)arylene, -O-(6-10C)arylene, (6-10C)arylene-O-, (2-9C)heteroarylene, -O-(2-9C)heteroarylene, (2-9C)heteroarylene-O- and (3-6C)heterocyclene, wherein each cycloalkylene is unsubstituted or substituted with from 1 to 4 substitutents selected independently from (1-4C)alkyl, and each arylene, heteroarylene or heterocyclene group is unsubstituted or substituted with from 1 to 4 substituents independently selected from halo, (1-4C)alkyl, (1-4C)alkoxy, –S-(1-4C)alkyl, -S(O)-(1-4C)alkyl, $-S(O)_2$-(1-4C)alkyl, -C(O)O(1-4C)alkyl, carboxy, cyano, hydroxy, nitro, trifluoromethyl and trifluoromethoxy;

Q is selected from a bond, -O-, -C(O)O-, -OC(O)-, -S-, -S(O)-, $-S(O)_2$-, $-N(Q^a)C(O)$-, $-C(O)N(Q^b)$-, $-N(Q^c)S(O)_2$-, $-S(O)_2N(Q^d)$-, $-N(Q^e)C(O)N(Q^f)$-, $-N(Q^g)S(O)_2N(Q^h)$-, $-OC(O)N(Q^i)$-, $-N(Q^j)C(O)O$- and $-N(Q^k)$;

$Q^a$, $Q^b$, $Q^c$, $Q^d$, $Q^e$, $Q^f$, $Q^g$, $Q^h$, $Q^i$, $Q^j$ and $Q^k$ are each independently selected from hydrogen, (1-6C)alkyl, $A^3$ and (1-4C)alkylene-$A^4$, wherein the alkyl group is unsubstituted or substituted with from 1 to 3 substituents independently selected from fluoro, hydroxy and (1-4C)alkoxy; or together with the nitrogen atom and the group $R^{4b}$ or $R^{4c}$ to which they are attached, form a 4-6 membered azacycloalkylene group;

$A^3$ and $A^4$ are each independently selected from (3-6C)cycloalkyl, (6-10C)aryl, (2-9C)heteroaryl and (3-6C)heterocyclyl, wherein each cycloalkyl is unsubstituted or substituted with from 1 to 4 substitutents selected independently from (1-4C)alkyl and each aryl, heteroaryl or heterocyclyl group is unsubstituted or substituted with from 1 to 4 substituents independently selected from halo, (1-4C)alkyl and (1-4C)alkoxy;

provided that the number of contiguous atoms in the shortest chain between the two nitrogen atoms to which $R^4$ is attached is in the range of from 4 to 16;

or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.

20. Canceled.

21. (Currently Amended) The compound of ~~any one of Claims 18, 19 or 20~~ Claim 19, wherein the number of contiguous atoms in the shortest chain between the two nitrogen atoms to which $R^4$ is attached is in the range of from 8 to 14.

22. (Currently Amended) The compound of ~~any one of Claims 18, 19 or 20~~ Claim 19, wherein the number of contiguous atoms in the shortest chain between the two nitrogen atoms to which $R^4$ is attached is 8, 9, 10 or 11.

23. (Currently Amended) The compound of ~~any one of Claims 18, 19 or 20~~ Claim 19, wherein $R^4$ is a divalent group of the formula: $-(R^{4a})_d-$ where $R^{4a}$ is (4-10C)alkylene.

24. (Original) The compound of Claim 23, wherein $R^4$ is $-(CH_2)_8-$, $-(CH_2)_9$, and $-(CH_2)_{10}-$.

25. (Currently Amended) The compound of ~~any one of Claims 18, 19 or 20~~ Claim 19, wherein $R^4$ is a divalent group of the formula:

$$-(R^{4a})_d-(A^2)_h-(R^{4d})_i-$$

wherein $R^{4a}$ is (1-10C)alkylene; $A^2$ is (6-10C)arylene or (2-9C)heteroarylene; and $R^{4d}$ is (1-10C)alkylene.

26. (Currently Amended) The compound of ~~any one of Claims 18, 19 or 20~~ Claim 19, wherein $R^4$ is a divalent group of the formula:

$$-(R^{4a})_d-Q-(A^2)_h-(R^{4d})_i-$$

wherein Q is -O- or $-N(Q^k)-$; $Q^k$ is hydrogen or (1-3C)alkyl; $R^{4a}$ is (1-10C)alkylene; $A^2$ is (6-10C)arylene or (2-9C)heteroarylene; and $R^{4d}$ is (1-10C)alkylene.

27. (Currently Amended) The compound of ~~any one of Claims 18, 19 or 20~~ Claim 19, wherein Q is $-N(Q^a)C(O)-$ or $-C(O)N(Q^b)-$.

28. (Original) The compound of Claim 27 wherein $R^4$ is selected from:



wherein m is an integer from 2 to 10; and n is an integer from 2 to 10; provided that m + n is an integer from 4 to 12;



wherein o is an integer from 2 to 7; and p is an integer from 1 to 6; provided that o + p is an integer from 3 to 8; and wherein the phen-1,4-ylene group is optionally substituted with from 1 to 4 substituents independently selected from halo, (1-4C)alkyl, (1-4C)alkoxy, –S-(1-4C)alkyl, -S(O)-(1-4C)alkyl, $-S(O)_2$-(1-4C)alkyl, -C(O)O(1-4C)alkyl, carboxy, cyano, hydroxy, nitro, trifluoromethyl and trifluoromethoxy;



wherein q is an integer from 2 to 6; r is an integer from 1 to 5; and s is an integer from 1 to 5; provided that q + r + s is an integer from 4 to 8; and wherein the phen-1,4-ylene group is optionally substituted with from 1 to 4 substituents independently selected from halo, (1-4C)alkyl, (1-4C)alkoxy, –S-(1-4C)alkyl, -S(O)-(1-4C)alkyl, -$S(O)_2$-(1-4C)alkyl, -C(O)O(1-4C)alkyl, carboxy, cyano, hydroxy, nitro, trifluoromethyl and trifluoromethoxy;



wherein t is an integer from 2 to 10; and u is an integer from 2 to 10; provided that t + u is an integer from 4 to 12;



wherein v is an integer from 2 to 7; and w is an integer from 1 to 6; provided that v + w is an integer from 3 to 8; and wherein the phen-1,4-ylene group is optionally substituted with from 1 to 4 substituents independently selected from halo, (1-4C)alkyl, (1-4C)alkoxy, –S-(1-4C)alkyl, -S(O)-(1-4C)alkyl, -$S(O)_2$-(1-4C)alkyl, -C(O)O(1-4C)alkyl, carboxy, cyano, hydroxy, nitro, trifluoromethyl and trifluoromethoxy; and



wherein x is an integer from 2 to 6; y is an integer from 1 to 5; and z is an integer from 1 to 5; provided that x + y + z is an integer from 4 to 8; and wherein the phen-1,4-ylene group is optionally substituted with from 1 to 4 substituents independently selected

from halo, (1-4C)alkyl, (1-4C)alkoxy, –S-(1-4C)alkyl, -S(O)-(1-4C)alkyl, -S(O)$_2$-(1-4C)alkyl, -C(O)O(1-4C)alkyl, carboxy, cyano, hydroxy, nitro, trifluoromethyl and trifluoromethoxy.

29. (Currently Amended) The compound of ~~any one of Claims 18, 19 or 20~~ Claim 19, wherein $R^4$ is selected from:

-$(CH_2)_7$-;

-$(CH_2)_8$-;

-$(CH_2)_9$-;

-$(CH_2)_{10}$-;

-$(CH_2)_{11}$-;

-$(CH_2)_2C(O)NH(CH_2)_5$-;

-$(CH_2)_2N(CH_3)C(O)(CH_2)_5$-;

-$(CH_2)_2C(O)NH$(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2NHC(O)$(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2NHC(O)NH(CH_2)_5$-;

-$(CH_2)_3NHC(O)NH(CH_2)_5$-;

-$(CH_2)_2C(O)NHCH_2$(cyclohex-1,3-ylene)$CH_2$-;

-$(CH_2)_2NHC(O)$(*cis*-cyclopent-1,3-ylene)-;

-$(CH_2)_2NHC(O)NH$(phen-1,4-ylene)$(CH_2)_2$-;

1-[-$(CH_2)_2C(O)$](piperidin-4-yl)$(CH_2)_2$-;

-$(CH_2)_2NHC(O)$(*trans*-cyclohex-1,4-ylene)$CH_2$-;

-$(CH_2)_2NHC(O)$(*cis*-cyclopent-1,3-ylene)-;

-$(CH_2)_2NH$(phen-1,4-ylene)$(CH_2)_2$-;

1-[-$(CH_2)_2NHC(O)$](piperidin-4-yl)$(CH_2)_2$-;

-$CH_2$(phen-1,4-ylene)NH(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2C(O)NHCH_2$(phen-1,3-ylene)$CH_2$-;

-$(CH_2)_2C(O)NHCH_2$(pyrid-2,6-ylene)$CH_2$-;

-$(CH_2)_2C(O)NH$(*cis*-cyclohex-1,4-ylene)$CH_2$-;

-$(CH_2)_2C(O)NH$(*trans*-cyclohex-1,4-ylene)$CH_2$-;

-$(CH_2)_2$NHC(O)(*cis*-cyclopent-1,3-ylene)$CH_2$-;

-$(CH_2)_2$N($CH_3$)C(O)(phen-1,3-ylene)$CH_2$-;

-$(CH_2)_2$N($CH_3$)C(O)(*trans*-cyclohex-1,4-ylene)$CH_2$-;

-$(CH_2)_2$C(O)NH(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$C(O)NH(phen-1,4-ylene)C*H($CH_3$)- ((*S*)-isomer);

-$(CH_2)_2$C(O)NH(phen-1,4-ylene)C*H($CH_3$)- ((*R*)-isomer);

2-[(S)-(-$CH_2$-](pyrrolidin-1-yl)C(O)$(CH_2)_4$-;

2-[(S)-(-$CH_2$-](pyrrolidin-1-yl)C(O)(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$C(O)NH(4-chlorophen-1,3-ylene)$CH_2$-;

-$CH_2$(2-fluorophen-1,3-ylene)$CH_2$-;

-$(CH_2)_2$C(O)NH(4-methylphen-1,3-ylene)$CH_2$-;

-$(CH_2)_2$C(O)NH(6-chlorophen-1,3-ylene)$CH_2$-;

-$(CH_2)_2$C(O)NH(2-chlorophen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$C(O)NH(2,6-dichlorophen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$NHC(O)NH$CH_2$(phen-1,3-ylene)$CH_2$-;

4-[-$CH_2$-](piperidin-1-yl)C(O)(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$C(O)N($CH_2CH_3$)(phen-1,4-ylene)$CH_2$-;

1-[-$(CH_2)_2$NHC(O)](piperidin-4-yl)-;

-$(CH_2)_2$C(O)NH(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_2$NHC(O)(thien-2,5-ylene)$CH_2$-;

-$(CH_2)_2$N($CH_3$)C(O)(3-nitrophen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$N($CH_3$)C(O)(*trans*-cyclohex-1,4-ylene)-;

1-[-$CH_2$(2-fluorophen-1,3-ylene)$CH_2$](piperidin-4-yl)-;

5-[-$(CH_2)_2$NHC(O)](pyrid-2-yl)$CH_2$-;

-$(CH_2)_2$(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_3$(thien-2,5-ylene)$(CH_2)_3$-;

-$(CH_2)_2$(phen-1,4-ylene)NH(phen-1,4-ylene)$(CH_2)_2$-;

-$CH_2$(phen-1,2-ylene)NH(phen-1,4-ylene)$(CH_2)_2$-;

1-[-$CH_2$(2-fluorophen-1,3-ylene)$CH_2$](piperidin-4-yl)$(CH_2)_2$-;

1-[-$CH_2$(2-fluorophen-1,3-ylene)$CH_2$](piperidin-4-yl)$CH_2$-;

-$(CH_2)_2C(O)NH$(3-chlorophen-1,4-ylene)$CH_2$-;

-$(CH_2)_2C(O)NH$(2-($CF_3O$-)phen-1,4-ylene)$CH_2$-;

-$(CH_2)_3$(phen-1,3-ylene)$NH$(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_2S(O)_2NH(CH_2)_5$-;

-$CH_2$(phen-1,3-ylene)$NH$(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_2C(O)NH$(2-iodophen-1,4-ylene)$CH_2$-;

-$(CH_2)_2C(O)NH$(2-chloro-5-methoxyphen-1,4-ylene)$CH_2$-;

-$(CH_2)_2C(O)NH$(2-chloro-6-methylphen-1,4-ylene)$CH_2$-;

-$(CH_2)_2C(O)NH(CH_2)_5$-;

-$(CH_2)_2N(CH_3)S(O)_2$(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2C(O)NH$(2-bromophen-1,4-ylene)$CH_2$-;

-$(CH_2)_3$(phen-1,4-ylene)$NH$(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_3$(phen-1,2-ylene)$NH$(phen-1,4-ylene)$(CH_2)_2$-;

1-[-$CH_2$(2-fluorophen-1,3-ylene)$CH_2$](piperidin-4-yl)$(CH_2)_3$-;

-$(CH_2)_2C(O)NH$(2-methoxyphen-1,4-ylene)$CH_2$-;

-$(CH_2)_5NH$(phen-1,4-ylene)$(CH_2)_2$-;

4-[-$(CH_2)_2$-](piperidin-1-yl)(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_2C(O)NH$(phen-1,4-ylene)$CH(CH_3)CH_2$-;

-$(CH_2)_2$-(*trans*-cyclohex-1,4-ylene)$NH$(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_2C(O)NH$(2-fluorophen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$(phen-1,3-ylene)$NH$(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_2C(O)NH$(2,5-difluorophen-1,4-ylene)$CH_2$-;

-$(CH_2)_2NHC(O)$(phen-1,4-ylene)$(CH_2)_2$-;

1-[-$CH_2$(pyrid-2,6-ylene)$CH_2$](piperidin-4-yl)$CH_2$-;

-$(CH_2)_3NH$(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_2NH$(naphth-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_3O$(phen-1,4-ylene)$CH_2$-;

1-[-$(CH_2)_3$](piperidin-4-yl)$CH_2$-;

4-[-$(CH_2)_2$](piperidin-1-yl)$C(O)$(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_3$(phen-1,4-ylene)$NHC(O)(CH_2)_2$-;

-$(CH_2)_3O$(phen-1,4-ylene)$(CH_2)_2$-;

2-[-$(CH_2)_2$](benzimidazol-5-yl)$CH_2$-;

-$(CH_2)_2$-(*trans*-cyclohex-1,4-ylene)NHC(O)$(CH_2)_2$-;

-$(CH_2)_2$-(*trans*-cyclohex-1,4-ylene)NHC(O)$(CH_2)_4$-;

-$(CH_2)_2$-(*trans*-cyclohex-1,4-ylene)NHC(O)$(CH_2)_5$-;

4-[-$(CH_2)_2$](piperidin-1-yl)C(O)$(CH_2)_2$-;

-$(CH_2)_2$NHC(O)NH(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2N(CH_3)(CH_2)_2$(*cis*-cyclohex-1,4-ylene)-;

-$(CH_2)_2$C(O)NH(2,3,5,6-tetrafluorophen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$C(O)NH(2,6-diiodophen-1,4-ylene)$CH_2$-;

4-[-$(CH_2)_2$](piperidin-1-yl)C(O)$(CH_2)_3$-;

4-[-$(CH_2)_2$](piperidin-1-yl)C(O)$(CH_2)_4$-;

4-[-$(CH_2)_2$](piperidin-1-yl)C(O)$(CH_2)_5$-;

-$(CH_2)_2$C(O)NH$CH_2$(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$NHC(O)NH$CH_2$(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$C(O)NH(2-methylphen-1,4-ylene)$CH_2$-;

1-[-$(CH_2)_3O$(phen-1,4-ylene)$(CH_2)_2$](piperidin-4-yl)$CH_2$-;

-$(CH_2)_2$C(O)NH$CH_2$(phen-1,3-ylene)$(CH_2)_2$-;

-$(CH_2)_2O$(phen-1,3-ylene)$CH_2$-;

-$(CH_2)_2N(CH_3)$C(O)$CH_2O$(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2N(CH_3)$C(O)$CH_2O$(phen-1,3-ylene)$CH_2$-;

-$(CH_2)_2N(CH_3)$C(O)(fur-2,5-ylene)$CH_2$-;

-$(CH_2)_2N(CH_3)$C(O)(thien-2,5-ylene)$CH_2$-;

-$(CH_2)_2O$(phen-1,4-ylene)$O(CH_2)_2$-;

-$(CH_2)_2$(*trans*-cyclohex-1,4-ylene)NHC(O)(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$(*trans*-cyclohex-1,4-ylene)NHC(O)$CH_2O$(phen-1,2-ylene)$CH_2$-;

-$(CH_2)_2$(*trans*-cyclohex-1,4-ylene)NHC(O)$CH_2O$(phen-1,3-ylene)$CH_2$-;

-$(CH_2)_2$(*trans*-cyclohex-1,4-ylene)NHC(O)$CH_2O$(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$(*trans*-cyclohex-1,4-ylene)NHC(O)(fur-2,5-ylene)$CH_2$-;

-$(CH_2)_2$(*trans*-cyclohex-1,4-ylene)NHC(O)(thien-2,5-ylene)$CH_2$-;

4-[-$(CH_2)_2$](piperidin-1-yl)C(O)$CH_2$O(phen-1,2-ylene)$CH_2$-;

4-[-$(CH_2)_2$](piperidin-1-yl)C(O)$CH_2$O(phen-1,3-ylene)$CH_2$-;

4-[-$(CH_2)_2$](piperidin-1-yl)C(O)$CH_2$O(phen-1,4-ylene)$CH_2$-;

4-[-$(CH_2)_2$](piperidin-1-yl)C(O)(fur-2,5-ylene)$CH_2$-;

4-[-$(CH_2)_2$](piperidin-1-yl)C(O)(thien-2,5-ylene)$CH_2$-;

-$(CH_2)_2$(phen-1,4-ylene)NHC(O)(phen-1,3-ylene)$CH_2$-;

-$(CH_2)_2$(phen-1,4-ylene)NHC(O)(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$(phen-1,4-ylene)NHC(O)$CH_2$O(phen-1,2-ylene)$CH_2$-;

-$(CH_2)_2$(phen-1,4-ylene)NHC(O)$CH_2$O(phen-1,3-ylene)$CH_2$-;

-$(CH_2)_2$(phen-1,4-ylene)NHC(O)$CH_2$O(phen-1,4-ylene)$CH_2$-;

-$(CH_2)_2$(phen-1,4-ylene)NHC(O)(fur-2,5-ylene)$CH_2$-;

-$(CH_2)_2$(phen-1,4-ylene)NHC(O)(thien-2,5-ylene)$CH_2$-;

-$(CH_2)_2$(*trans*-cyclohex-1,4-ylene)NHC(O)(phen-1,3-ylene)$CH_2$-;

-$(CH_2)_3$O(phen-1,3-ylene)$CH_2$-;

-$CH_2CH(OH)CH_2$NH(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_4$NH(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_2$C(O)NH(phen-1,4-ylene)$CH_2$NHC(O)$CH_2$-;

-$(CH_2)_2$C(O)NH(phen-1,4-ylene)$(CH_2)_2$NHC(O)$CH_2$-;

-$(CH_2)_2$C(O)NH$CH_2$(*trans*-cyclohex-1,4-ylene)$CH_2$-;

-$(CH_2)_2$NHC(O)$(CH_2)_5$-;

-$(CH_2)_2$O(phen-1,3-ylene)O$(CH_2)_2$-;

-$(CH_2)_2$O(phen-1,2-ylene)O$(CH_2)_2$-;

-$CH_2$(phen-1,2-ylene)O(phen-1,2-ylene)$CH_2$-;

-$(CH_2)_2$C(O)NH$(CH_2)_6$-;

-$(CH_2)_3$(phen-1,4-ylene)$(CH_2)_3$-;

-$(CH_2)_3$(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_4$(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_3$(furan-2,5-ylene)$(CH_2)_3$-;

-$(CH_2)_2$N$(CH_3)$C(O)NH(phen-1,4-ylene)$(CH_2)_2$-;

4-[-$(CH_2)_2$](piperidin-1-yl)C(O)NH(phen-1,4-ylene)$(CH_2)_2$-;

-$(CH_2)_3$(phen-1,3-ylene)$(CH_2)_3$-;
-$(CH_2)_3$(tetrahydrofuran-2,5-ylene)$(CH_2)_3$-; and
-$(CH_2)_2O$(phen-1,4-ylene)$C(O)(CH_2)_2$-.

30. Canceled.

31. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of any one of ~~Claims 1, 18, 19, 20 or 30~~ Claims 19 to 29.

32-40. Canceled.